<DOC>
	<DOC>NCT01739283</DOC>
	<brief_summary>Investigation of Glucose-dependent Insulinotropic Polypeptide (GIP) effects at hyper and hypoglycemia in type 1 diabetes.</brief_summary>
	<brief_title>GIP and GLP-1 in Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<criteria>• Diagnosed with type 1 diabetes (WHO criteria) HbA1c &gt; 9 % Liver disease (ALAT/ASAT &gt; 2 x upper normal limit) Diabetic nephropathy (screatinine &gt; 130 µM or albuminuria) Proliferative diabetic retinopathy (anamnestic) Severe arteriosclerosis or heart failure (NYHA group III or IV) Anemia treatment with medication not applicable to pause for 12 hours Cpeptide increase after 50 g iv arginine</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>